TORCHLIGHT trial, brightening the life of more patients with advanced triple-negative breast cancer.

Transl Breast Cancer Res · 2024 · PMC11094406 · PMID 38751675

Europe PMC DOI

hedged sentence

0.0148

closest p · 0.3× alpha

0.0148

boldest claim

The sentences

showed a trendP=0.0148actually significant

5.6 months, hazard ratio (HR): 0.653, 95% CI: 0.470–0.906, P=0.0102], furthermore, showed a trend towards improved OS (in PD-L1 positive subgroup: 32.8 vs. 19.5 months, HR: 0.615, 95% CI: 0.414–0.914, P=0.0148; in intent-to-treat (ITT) population: 33.1 vs. 23.5 months, HR: 0.691, 95% CI: 0.513–0.932, P=0.0145).

also in 11,799 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.